McGill University, Montreal, Quebec, H3A 0G4, Canada.
Epigenomics. 2022 Mar;14(6):309-314. doi: 10.2217/epi-2021-0483. Epub 2021 Dec 8.
In this interview, Professor Moshe Szyf speaks with Storm Johnson, Commissioning Editor for , on his work to date in the field of social epigenetics. Szyf received his PhD from the Hebrew University and did his postdoctoral fellowship in genetics at Harvard Medical School, joined the Department of Pharmacology and Therapeutics at McGill University in Montreal in 1989 and is a fellow of the Royal Society of Canada and the Academy of Health Sciences of Canada. He is the founding codirector of the Sackler Institute for Epigenetics and Psychobiology at McGill and is a Fellow of the Canadian Institute for Advanced Research Experience-Based Brain and Biological Development program. Szyf was the founder of the first pharma to develop epigenetic pharmacology, Methylgene Inc., and the journal . The Szyf lab proposed two decades ago that DNA methylation is a prime therapeutic target in cancer and other diseases and postulated and provided the first set of evidence that the social environment early in life can alter DNA methylation, launching the emerging field of social epigenetics.
在本次访谈中，莫舍·西弗教授（Moshe Szyf）与 期刊的委托编辑斯图尔特·约翰逊（Storm Johnson）畅谈了他在社会表观遗传学领域迄今的工作。西弗教授在希伯来大学获得博士学位，在哈佛医学院从事遗传学博士后研究，于 1989 年加入加拿大蒙特利尔麦吉尔大学药理学和治疗学系，是加拿大皇家学会和加拿大健康科学院的院士。他是麦吉尔大学萨克勒表观遗传学和心理生物学研究所的创始联合主任，也是加拿大高级研究所经验为基础的大脑和生物发育项目的研究员。西弗教授是第一家开发表观遗传学药物的制药公司——美吉基因公司（Methylgene Inc.）和期刊 的创始人。二十年前，西弗实验室提出 DNA 甲基化是癌症和其他疾病的主要治疗靶点，并假设并提供了第一批证据，证明生命早期的社会环境可以改变 DNA 甲基化，从而开创了新兴的社会表观遗传学领域。
